Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension.

Abstract

BACKGROUND/AIMS:

To evaluate the efficacy of brimonidine purite versus dorzolamide given twice daily in primary open angle glaucoma or ocular hypertensive subjects.

METHODS:

In this double masked, multicentre, prospective, crossover comparison 33 subjects were randomised to brimonidine purite or dorzolamide for the first 4 week treatment period after a 4 week washout. Subjects began the opposite treatment for the second 4 week period after another 4 week washout. Intraocular pressure (IOP) was measured at 08:00 (trough) and 10:00, 18:00, and 20:00 hours after dosing at each baseline and at the end of each treatment period.

RESULTS:

The baseline diurnal IOP was 22.9 (SD 2.8) for brimonidine purite and 22.2 (SD 2.4) mm Hg for dorzolamide. The trough IOP following 4 weeks of therapy was 21.0 (SD 3.7) for brimonidine purite and 21.0 (SD 3.1) mm Hg for dorzolamide (p = 0.90). The mean diurnal IOP was 19.3 (SD 3.1) for brimonidine purite and 19.8 (SD 2.4) mm Hg for dorzolamide (p = 0.46). Dorzolamide caused more ocular stinging upon instillation (n = 8) than brimonidine purite (n = 1) (p = 0.02). No statistical differences existed between groups for systemic adverse events.

CONCLUSIONS:

This study suggests that brimonidine purite and dorzolamide each given twice daily have similar efficacy in primary open angle glaucoma or ocular hypertensive subjects. However, a trend was observed at 10:00 of greater brimonidine purite efficacy compared with dorzolamide.

• Authors: E D Sharpe, D G Day, C J Beischel, J S Rhodes, J A Stewart, W C Stewart
• Journal: The British journal of ophthalmology (Br J Ophthalmol) Vol. 88 Issue 7 Pg. 953-6 (Jul 2004) ISSN: 0007-1161 [Print] England
• PMID: 15205246 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antihypertensive Agents
• Quinoxalines
• Sulfonamides
• Thiophenes
• Brimonidine Tartrate
• dorzolamide

Topics

• Antihypertensive Agents (administration & dosage, adverse effects)
• Brimonidine Tartrate
• Cross-Over Studies
• Double-Blind Method
• Drug Administration Schedule
• Female
• Glaucoma, Open-Angle (drug therapy)
• Humans
• Intraocular Pressure (drug effects)
• Male
• Middle Aged
• Ocular Hypertension (drug therapy)
• Prospective Studies
• Quinoxalines (administration & dosage, adverse effects)
• Sulfonamides (administration & dosage, adverse effects)
• Thiophenes (administration & dosage, adverse effects)